Xconomy Forum: Pharma’s Bet on Boston Innovation

November 4, 2009 – Agenda
1:15 – 2:00
2:00 – 2:05 Welcome and Opening Remarks
Bob Buderi, Founder and Editor in Chief, Xconomy
Michelle Dipp, Head of US CEEDD, GlaxoSmithKline
2:05 – 2:35 Keynote: Biotech and Innovation in Boston
Christoph Westphal, CEO, Sirtris; SVP, Centre of Excellence for External Drug Discovery, GlaxoSmithKline
2:35 – 2:50 Innovation Profile: Aileron Therapeutics
Joseph Yanchik III,
 President and CEO
2:50 – 3:40 Pharma Ventures
Jean George, General Partner, Advanced Technology Ventures (moderator)
Russell Herndon, President and CEO, Hydra Biosciences
Maggie Flanagan LeFlore, Managing Director, MedImmune Ventures
Campbell Murray, Managing Director, Novartis Venture Funds
Daphne Zohar, Founder and Managing Partner, PureTech Ventures
3:40 – 4:00 Networking Break
4:00 – 4:15 Innovation Profile: Aveo Pharmaceuticals
Tuan Ha-Ngoc, President and CEO
4:15 – 4:30 Innovation Profile: Enlight Biosciences
David Steinberg, Founding CEO
4:30 – 4:45 Innovation Profile: Merck’s Acquisition of GlycoFi
Natarajan Sethuraman, Senior Director, Merck GlycoFi
4:45 – 5:30 Closing Address and Chat
Deborah Dunsire, CEO, Millennium: The Takeda Oncology Company
Interviewed by Noubar Afeyan, Co-founder, Managing Partner and CEO, Flagship Ventures
5:30 – 7:00
Networking Reception